As imaging continues to transform the diagnosis and treatment of urological cancers, the EAU Section of Urological Imaging Annual Meeting has become a familiar and highly anticipated start to the EMUC Congress (Brussels, 5-8 Nov 2026). In the lead up to the 1-day meeting on Thursday 5 November, section chair Prof. Francesco Sanguedolce (ES) highlights key themes from the scientific programme, with a focus on the discussion of practice-changing trials in urological imaging.
Prof. Sanguedolce: “The imaging meeting at EMUC is a key forum for specialists with a common interest for the management of urological cancer to stay at the forefront of innovation.” He emphasises that the multidisciplinary nature of the meeting reflects how modern cancer care should be delivered. “Imaging today is not just about diagnosis. It influences treatment selection, surgical planning, response assessment and follow-up. Bringing experts from different disciplines together creates a unique environment for discussion and collaboration.”
“This year’s meeting has been designed around a simple but ambitious objective”, Prof. Sanguedolce says. “Rather than just presenting new imaging data, we want to critically review the studies that are changing clinical practice. One of the distinctive features of the meeting will be its highly interactive format”, he explains. “Every session has been designed not only to present the latest evidence but also to stimulate discussion through expert panels, case-based debates and extensive audience participation. The value of the meeting lies not only in the topics themselves, but also in the way they are discussed.”
The goal, he adds, is “to move beyond simply reviewing the literature and to explore how these innovations should shape clinical practice. The meeting offers a unique opportunity to discuss the latest evidence directly with the experts who have done the research.”
The scientific programme covers the full spectrum of modern urological imaging, and plenary sessions include:
- Practice-changing MRI trials in prostate cancer
- The latest advances in PSMA PET imaging
- Artificial intelligence in urological cancers, from diagnosis to image-guided surgery
- Practice-changing trials in bladder cancer
- Imaging-driven treatment decision-making in bladder cancer
- Emerging technologies in renal cancer, including molecular imaging, theranostics and histotripsy
Another highlight will be the dedicated ‘Best Imaging Abstract Award Session’, where the most impactful research submitted to the meeting will be presented and recognised.
Beyond the scientific sessions, Prof. Sanguedolce also emphasised the importance of bringing the imaging community together. The meeting provides an ideal setting to exchange ideas, discuss future collaborations and strengthen professional networks across Europe and beyond.
“We sincerely hope you will join us in Brussels, he concludes, “for what promises to be an exciting day of science, innovation and discussion.”
